Kasia Siwek, Sanofi's country medical head for Australia and NZ, said, “At Sanofi, we are proud of our ongoing work with both the Australian clinical community and the government to broaden access to LIBTAYO as a first-line treatment for eligible Australians diagnosed with metastatic NSCLC. …
Sanofi welcomes new lung cancer listing for immune checkpoint inhibitor
April 4, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy
July 2, 2026 - - Australian Biotech -
The end-game of strong-arming companies over prices at the expense of patients and process
July 2, 2026 - - Latest News -
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - - Latest News -
Commercial outsourcing emerges as a strategic option to patient access
July 1, 2026 - - Latest News -
The minister is following a tried and tested process, but what is the risk in this new world?
July 1, 2026 - - Latest News -
Patient alarm over the potential loss of subsidised access to MS medicines
July 1, 2026 - - Latest News -
Protection gap leaves older Australians vulnerable this winter
July 1, 2026 - - Latest News